Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Eligibility Criteria

• 1. Subjects age 18-89 years old with pleural effusion or peritoneal ascites due to metastatic cancer
• 2. Scheduled to undergo standard-of-care placement of pleural or peritoneal drainage catheter
• 3. ECOG performance status: 0-2
• 4. Able to read and sign consent form in English and provide informed consent
• 1. Laboratory abnormalities that indicate clinically significant inflammatory process AST/SGOT \> 2 times the upper limit of normal ALT/SGPT \> 2 times the upper limit of normal Total bilirubin \> 2 times the upper limit of normal Creatinine \> 2 times the upper limit of normal Hemoglobin \< 8gm/dL White blood cell count \< 3,000/ mm3 Platelet count \< 70,000/mm3 Absolute neutrophil cell count \< 2,000 per mm3
• 2. Subjects who are unable to comply with study procedures including travel for weekly outpatient clinic visits
• 3. Pregnant women
• 4. Active immunotherapy within 30 days; concurrent chemotherapy or targeted therapy is permitted but for patients with a history of prior immunotherapy, the most recent dose should be \>30 days prior to the first treatment visit
• 5. Investigational drug use within 30 days prior to first treatment dose
• 6. History of systemic autoimmune disease
• 7. Patient with known hypersensitivity to tocilizumab
• 8. Active infection
• 9. Medical contraindication or history of adverse reaction to acetaminophen or diphenhydramine